IL1R1 and breast carcinoma: We assessed the effects of these inhibitors on parameters associated with tumour growth and metastasis in mouse mammary cancer cell lines E0771 and Py8119 and compared results with the FDA/NICE approved IL1Ra biologics agent Anakinra which has been shown to produce promising effects in blocking breast cancer metastasis to bone in previous studies [2,12,13].